MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome, discovered by the Cohens laboratory at USC in 2015. It represents a new class of mitochondrial signalling peptides that regulate metabolism systemically — circulating from mitochondria through the bloodstream to act on distant tissues including skeletal muscle and the liver. MOTS-c has attracted significant research interest for its effects on insulin sensitivity, exercise performance, and metabolic aging.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
MOTS-c is a mitochondrial peptide that activates AMPK to improve insulin sensitivity, fat oxidation, and metabolic function. It mimics aspects of the metabolic response to exercise, including improved mitochondrial function and glucose uptake in skeletal muscle. It has shown anti-obesity, longevity-promoting, and exercise performance effects in animal research.
How Does MOTS-c Work?
MOTS-c's primary mechanism involves activation of AMPK (AMP-activated protein kinase), the cellular energy sensor that responds to metabolic stress. When cellular energy drops (during exercise, fasting, or caloric restriction), AMPK activates pathways that increase fatty acid oxidation, improve insulin sensitivity, and promote mitochondrial biogenesis. MOTS-c appears to directly activate this pathway, mimicking aspects of the metabolic response to exercise.
In skeletal muscle specifically, MOTS-c improves insulin-stimulated glucose uptake independent of the insulin receptor pathway — suggesting it can restore insulin sensitivity through a bypass mechanism relevant to insulin-resistant states.
MOTS-c also modulates the folate cycle and one-carbon metabolism, affecting methylation reactions important for gene expression regulation. This may contribute to its observed effects on aging and cellular function beyond direct metabolic signalling.
Key Research Findings
MOTS-c was discovered when researchers noted that the mitochondrial genome's 12S rRNA gene contained a small open reading frame — an overlooked potential protein-coding region. When they synthesised and tested the peptide, it showed dramatic metabolic effects in mice: improved insulin sensitivity, reduced obesity on high-fat diet, improved exercise performance, and increased longevity.
Exercise mimicry is one of the most studied aspects: MOTS-c administration to sedentary mice produced metabolic improvements similar to exercise training, including improved mitochondrial function and fat oxidation. A subsequent study showed MOTS-c levels in human blood increase during exercise, suggesting it functions as an exercise signal.
Age-related decline of MOTS-c has been documented in humans — plasma levels are higher in young adults and decline with aging, consistent with the metabolic decline of aging. Centenarian studies found higher MOTS-c levels in long-lived individuals compared to average-lifespan controls, paralleling the Humanin longevity correlation.
Research Protocol Reference
| Protocol | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| Metabolic support | 5–10 mg/week | SubQ or IM | 2–3x weekly | Most common community protocol |
| Exercise performance | 5 mg | SubQ | Pre-workout | Timing aligned with exercise |
| Anti-aging maintenance | 5 mg | SubQ | Weekly | Low-dose longevity protocol |
Safety and Research Status
MOTS-c is a relatively recently discovered peptide (2015) with a limited community research history compared to BPC-157 or TB-500. Animal research shows no significant adverse effects. Human research is in early stages.
**Hypoglycaemia risk:** MOTS-c improves insulin sensitivity meaningfully. In individuals already using insulin-sensitising medications (metformin, GLP-1 agonists, insulin) or in those with naturally good insulin sensitivity, additive effects could theoretically produce hypoglycaemia. Monitoring blood glucose when starting MOTS-c is advisable.
**Stacking with Humanin:** The two mitochondrial peptides have complementary profiles — Humanin is more cytoprotective/neuroprotective, MOTS-c is more metabolic/exercise-mimetic. Combined protocols are used in longevity-focused research communities.
**Research limitation acknowledgement:** MOTS-c's research base is newer and more limited than many other peptides discussed here. The excitement around its discovery and mechanism is warranted, but translating from mouse studies to human protocols involves the usual uncertainty multiplier.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
MOTS-c is a mitochondrial peptide that activates AMPK to improve insulin sensitivity, fat oxidation, and metabolic function. It mimics aspects of the metabolic response to exercise, including improved mitochondrial function and glucose uptake in skeletal muscle. It has shown anti-obesity, longevity-promoting, and exercise performance effects in animal research.
No — both are mitochondrial-derived peptides but with different mechanisms. MOTS-c is primarily metabolic: AMPK activation, insulin sensitisation, exercise mimicry. Humanin is primarily cytoprotective: preventing cell death under stress, neuroprotection, cardiovascular protection. They are complementary and sometimes stacked together.
No — but it may partially mimic some metabolic adaptations of exercise. Research in sedentary mice showed MOTS-c producing metabolic improvements similar to exercise training. This doesn't mean it can replace the structural, cardiovascular, and neurological adaptations to actual exercise. The more accurate framing is that MOTS-c amplifies exercise-related metabolic signalling.
MOTS-c improves insulin sensitivity through AMPK activation and has shown reduced insulin resistance and improved glucose tolerance in animal models of diabetes and obesity. Human clinical data doesn't yet exist. It's being studied as a potential metabolic therapeutic.
MOTS-c levels decline with age in humans and are higher in centenarians than in average-lifespan individuals — suggesting it may mediate metabolic healthspan. In animal models, MOTS-c extends lifespan in aged mice. The hypothesis is that maintaining MOTS-c signalling as levels naturally decline with age may preserve metabolic function and healthy aging.
MOTS-c is typically administered via subcutaneous injection. Community protocols use 5–10 mg 2–3 times per week. Some protocols time it pre-workout to align with the exercise context in which endogenous MOTS-c levels naturally rise. Use the peptide calculator for reconstitution math.